Application of ER beta selective agonist in tumor resistance

An agonist and selective technology, applied in the field of biomedicine, can solve the problem of not reflecting the characteristics and mechanism of liquiritigenin on lung squamous cell carcinoma, and achieve the effect of promoting apoptosis and high sensitivity of lung squamous cell carcinoma cell lines.

Pending Publication Date: 2022-08-02
SHANGHAI JIAO TONG UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In previous studies on liquiritigenin, lung adenocarcinoma A549 cells were mostly used as the research object, and the conclusions obtained could not reflect the characteristics and mechanism of liquiritigenin on lung squamous cell carcinoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ER beta selective agonist in tumor resistance
  • Application of ER beta selective agonist in tumor resistance
  • Application of ER beta selective agonist in tumor resistance

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] 1. Materials and methods

[0035] 1.1 Materials: Liquiritigenin (HY-N0377, CAS No.: 578-86-9), (-)-(S)-equol ((-)-(S)-Equol, HY-100583, CAS No.: 531 -95-3), purchased from MCE. Cell culture reagents were purchased from Gibco. Other reagents were purchased from Biyuntian Biotechnology Co., Ltd. and Sigma Chemical Co..

[0036] 1.2 Method:

[0037] Cell culture: Lung squamous cell carcinoma cell lines H226, SK-MES-1, lung adenocarcinoma cell A549 and large cell lung cancer cell H460 were purchased from ATCC (ATCC, Rockville, MD, USA). The culture medium of H226, A549 and H460 cells is RPMI 1640 medium containing 10% fetal bovine serum. SK-MES-1 cell culture medium was DMEM medium containing 10% fetal bovine serum. And add 1 mL of penicillin and streptomycin mixture to each 100 mL of culture medium, that is, 1% double antibody, in 5% CO 2 , cultured in a 37°C cell incubator.

[0038] The 50% inhibitory concentration (IC50) of CCK8 assay: lung squamous cell carcinoma...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of an ER beta selective agonist in tumor resistance. At present, no valuable discovery is provided for finding a new target spot for treating the targeted squamous cell carcinoma, and in addition, clinical treatment medicines for the squamous cell carcinoma are poor in effectiveness, so that the finding of the new target spot for the targeted treatment of the squamous cell carcinoma and the development of the medicines for the targeted treatment of the squamous cell carcinoma have important significance. According to the application disclosed by the invention, the lung squamous cell carcinoma resisting effect of a natural compound library is screened, and the condition that the ER beta selective agonists liquiritigenin and (-)-(S)-equol have a remarkable effect on resisting the progress of lung squamous cell carcinoma is found. Experiments also show that liquiritigenin can induce apoptosis of lung squamous carcinoma cells by inhibiting a PI3K / Akt / mTOR pathway. Meanwhile, nude mouse in-vivo experiments also prove the anti-lung squamous cell carcinoma effect of liquiritigenin. Reference is provided for developing new targets for treating squamous cell carcinoma, especially lung squamous cell carcinoma, certain reference is provided for clinical medication of lung squamous cell carcinoma patients, and in addition, the molecular mechanism of liquiritigenin for treating lung squamous cell carcinoma is clarified.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of an ERβ selective agonist in anti-tumor, in particular to the application of an ERβ selective agonist liquiritigenin and (-)-(S)-equol in anti-squamous application in cancer. Background technique [0002] Lung cancer is the most common malignant tumor in the world, mainly divided into small cell lung cancer and non-small cell lung cancer. Non-small cell lung cancer accounts for about 85% of the total lung cancer, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, etc. Lung squamous cell carcinoma accounts for 30% of non-small cell lung cancers. At present, there is a lack of effective progress in the research on new targets for targeted therapy of lung squamous cell carcinoma, and there is also a lack of effective targeted drugs for patients with lung squamous cell carcinoma. Therefore, it is urgent to develop new targets for lung squ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/353A61P35/00
CPCA61K31/353A61P35/00A61K2300/00
Inventor 李欣燕陈剑
Owner SHANGHAI JIAO TONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap